IRWD Q1 2020 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$603M

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$80M+16.3% YoY

Gross Profit

$78M97.2% margin

Operating Income

$13M16.5% margin

Net Income

$3M4.2% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

-36.7%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$42M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$404M

Total Liabilities

$476M

Stockholders' Equity

-$72M

Cash & Equivalents

$232M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$69M	+16.3%
Gross Profit	$78M	$68M	+14.8%
Operating Income	$13M	-$54M	+124.3%
Net Income	$3M	-$59M	+105.6%

Revenue Segments

Collaborative Arrangement Co Promotion And Other Agreements

$945,00034%

License And Service

$900,00033%

Collaborative Arrangement Promotion Agreement

$900,00033%

Geographic Segments

U

$71M96%

Europe And Other

$643,0001%

Canada And Mexico

$600,0001%

Europe

$600,0001%

North America

$550,0001%

J

$400,0001%

China Hong Kong And Macau

$200,0000%